Has Jose Madrazo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $80 in general payments to Jose Madrazo, MD across 4 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jose Madrazo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jose Madrazo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jose Madrazo, MD

Cardiovascular Disease · Baltimore, MDNPI 1508984873

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 2024 is the largest year on record at $45, 2.2 times the $21 reported in 2022. That places this record below the midpoint for cardiovascular disease clinicians in MD, where the typical reported total is $1,418.

$80in general payments, 2019–2025

Across 4 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Irhythm Technologies, Inc.$45
E.r. Squibb & Sons, L.L.C.$35

$46,869in research payments, 2019–2025

Across 5 payments — averaging $9373.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$47K

What the payments were for

Food & beverage$80100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Irhythm Technologies, Inc.	2	$45
E.r. Squibb & Sons, L.L.C.	2	$35

How this compares

$80 in reported general payments places this provider in the 10th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Medicare billing

Part B allowed, 2024

$278,039

Medicare patients

3,301

Services billed

7,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CamzyosMavacamten	223	$1,790,639
JardianceEmpagliflozin	147	$160,255
EliquisApixaban	61	$86,271
XareltoRivaroxaban	17	$14,290
Metoprolol Succinate	97	$1,784
Verapamil SrVerapamil Hcl	20	$1,543
Carvedilol	60	$613
Atorvastatin Calcium	44	$552
Spironolactone	70	$540
Rosuvastatin Calcium	22	$501
Valsartan	25	$483
Ezetimibe	20	$475
Torsemide	22	$394
Verapamil ErVerapamil Hcl	16	$361
Losartan Potassium	46	$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos	$35	$1,790,639223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

Navin KapurBaltimore$1.5M
Michael BlahaBaltimore$609K
Sanjay RajagopalanBaltimore$521K
Erin MichosBaltimore$257K
Seth MartinBaltimore$166K
Erika FellerBaltimore$121K
Charles CummingsBaltimore$114K
John RickardBaltimore$109K
Christopher DefilippiBaltimore$101K
David KassBaltimore$90K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →